Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human, Randomized, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALTB-268 in Healthy Volunteers

Next Previous
Search
Trial Profile

A First-In-Human, Randomized, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALTB-268 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leiolizumab (Primary)
  • Indications Autoimmune disorders; Inflammation; Transplant rejection; Ulcerative colitis
  • Focus Adverse reactions; First in man
  • Sponsors AltruBio

    • Most Recent Events

    • 26 Sep 2023 According to an AltruBio media release,Status changed from recruiting to completed.
    • 01 Aug 2023 Results published in an AltruBio media release.
    • 31 May 2023 According to an AltruBio media release, the President and Chief Executive Officer Judy Chou, Ph.D., will present an in-person corporate overview at the 2023 BIO International Convention taking place June 5-8, 2023, in Boston, MA highlighting clinical trial progress of this trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top